Lakshman R. Sehgal

Biovec LLC develops new gene therapy products. The company was founded by David F. Wolf on August 3, 2015 and is headquartered in Chicago, IL.

Biovec BV operates as a life science company which focuses on developing new gene therapy products. It owns intellectual property for the viral vector delivery of a specific gene therapy expected to be a breakthrough in coronary by-pass surgery. The gene therapy causes the body to produce a natural anticoagulant expected to reduce the occlusion of the grafted veins and avoid medical interventions that would otherwise occur. The company was founded by David F. Wolf and Lakshman R. Sehgal in 2003 and is headquartered in Groningen, the Netherlands.